Akriti Jain, Leukemia and Myeloid Disorders Physician at Cleveland Clinic, shared a post on X:
“CML Updated from ASH 2024 – grateful for this opportunity to present at Cleveland Clinic ASH review!
- ASC4FIRST and
- Olverembatinib as 2L therapy
- Impact of ASXL1 on MMR, FFS and acquisition of TKD mutations, including a poster by us!”
